CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 26 enrolled
Drug / intervention
daily ingestion of Lactobacillus plantarum PS128dietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04389762
NCT04389762N/ACompleted
CompareCT.gov

Lactobacillus Plantarum PS128 May Improve Off Duration in Parkinson's Disease: a Pilot Study

Professor Lu Neurological Clinic·interventional·Posted May 15, 2020·Updated Aug 17, 2025

In Brief

A clinical study evaluating daily ingestion of Lactobacillus plantarum PS128 for Parkinson Disease. Completed, enrolled 26 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the short term effects (12 Weeks) of Lactobacillus plantarum PS128 (PS128) on Parkinson's disease (PD) symptoms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesTaiwan
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedMay 15, 2020
Enrollment StartJun 4, 2019
Primary CompletionMay 13, 2020
Study CompletionJun 13, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.1 years ago

Interventions

daily ingestion of Lactobacillus plantarum PS128dietary

daily ingestion of 60 billion colony forming unit (CFU) of Lactobacillus plantarum PS128 (30 billion CFU/capsule)